Asn215Ser, Ala143Thr, and Arg112Cys variants in α-galactosidase A protein confer stability loss in Fabry’s disease

References

• Al-Khafaji, K., & Taskin Tok, T. (2021). Amygdalin as multi-target anticancer drug against targets of cell division cycle: Double docking and molecular dynamics simulation. Journal of Biomolecular Structure & Dynamics, 39(6), 1965–1974. https://doi.org/10.1080/07391102.2020.1742792
   PubMed Web of Science ®Google Scholar
• Al-Khayyat, M. Z. S., & Al-Dabbagh, A. G. A. (2016). In silico prediction and docking of tertiary structure of LuxI, an inducer synthase of Vibrio fischeri. Reports of Biochemistry & Molecular Biology, 4(2), 66–75.
   PubMed Web of Science ®Google Scholar
• Benkert, P., Tosatto, S. C., & Schomburg, D. (2008). QMEAN: A comprehensive scoring function for model quality assessment. Proteins: Structure, Function, and Bioinformatics, 71(1), 261–277. https://doi.org/10.1002/prot.21715
   PubMed Web of Science ®Google Scholar
• Blaydon, D., Hill, J., & Winchester, B. (2001). Nov Fabry disease: 20 novel GLA mutations in 35 families. Human Mutation, 18(5), 459. https://doi.org/10.1002/humu.1219
   PubMedGoogle Scholar
• Bokhari, S., Zulfiqar, H., & Hariz, A. (2022). Fabry disease. StatPearls Publisher.
   Google Scholar
• Daison, F. A., Kumar, N., Balakrishnan, S., Venugopal, K., Elango, S., & Sokkar, P. (2022). Molecular dynamics studies on the bacterial membrane pore formation by small molecule antimicrobial agents. Journal of Chemical Information and Modeling, 62(1), 40–48.
   PubMed Web of Science ®Google Scholar
• Dong, Z.-Y., Wang, Q., Lin, S.-P., Chen, P., Liu, J.-N., Liu, S.-W., Cai, G.-Y., Chen, X.-M., & Hong, Q. (2020). GLA missense and promoter variants co-segregating in a Chinese family with Fabry disease. Annals of Translational Medicine, 8(14), 865–865. https://doi.org/10.21037/atm-19-4510
   PubMed Web of Science ®Google Scholar
• Durham, E., Dorr, B., Woetzel, N., Staritzbichler, R., & Meiler, J. (2009). Solvent accessible surface area approximations for rapid and accurate protein structure prediction. Journal of Molecular Modeling, 15(9), 1093–1108.
   PubMed Web of Science ®Google Scholar
• Gajjar, N. D., Dhameliya, T. M., & Shah, G. B. (2021). In search of RdRp and Mpro inhibitors against SARS CoV-2: Molecular docking, molecular dynamic simulations and ADMET analysis. Journal of Molecular Structure, 1239, 130488.
   PubMed Web of Science ®Google Scholar
• Garman, S. C. (2007). Structure–function relationships in α‐galactosidase A. Acta Paediatrica, 96(455), 6–16. https://doi.org/10.1111/j.1651-2227.2007.00198.x
   PubMedGoogle Scholar
• Germain, D., Biasotto, M., Tosi, M., Meo, T., Kahn, A., & Poenaru, L. (1997). Fluorescence-assisted mismatch analysis (FAMA) for exhaustive screening of the α-galactosidase A gene and detection of carriers in Fabry disease. Early Human Development, 49(3), 242–243. https://doi.org/10.1016/S0378-3782(97)90568-5
   Google Scholar
• Germain, D. P., Brand, E., Burlina, A., Cecchi, F., Garman, S. C., Kempf, J., Laney, D. A., Linhart, A., Maródi, L., Nicholls, K., Ortiz, A., Pieruzzi, F., Shankar, S. P., Waldek, S., Wanner, C., & Jovanovic, A. (2018). Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study. Molecular Genetics & Genomic Medicine, 6(4), 492–503. https://doi.org/10.1002/mgg3.389
   PubMed Web of Science ®Google Scholar
• Hasan, T., Jahan, E., Ahmed, K. S., Hossain, H., Siam, S., Nahid, N., Mazumder, T., Shuvo, M., & Daula, A. (2022). Rutin hydrate and extract from Castanopsis tribuloides reduces pyrexia via inhibiting microsomal prostaglandin E synthase-1. Biomedicine & Pharmacotherapy, 148, 112774. https://doi.org/10.1016/j.biopha.2022.112774
   PubMed Web of Science ®Google Scholar
• Hemelsoet, D., De Keyser, J., Van Heuverswyn, F., Willems, R., Vandekerckhove, H., Bondue, A., de Asmundis, C., Saenen, J., Van de Walle, S., Godart, P., Kampmann, C., Stepman, H., Poppe, B., & Terryn, W. (2021). Screening for Fabry disease in male patients with arrhythmia requiring a pacemaker or an implantable cardioverter–defibrillator. Circulation, 143(8), 872–874. https://doi.org/10.1161/CIRCULATIONAHA.120.051400
   PubMed Web of Science ®Google Scholar
• Heo, S. H., Kang, E., Kim, Y.-M., Go, H., Kim, K. Y., Jung, J. Y., Kang, M., Kim, G.-H., Kim, J.-M., Choi, I.-H., Choi, J.-H., Jung, S.-C., Desnick, R. J., Yoo, H.-W., & Lee, B. H. (2017). Fabry disease: Characterisation of the plasma proteome pre-and post-enzyme replacement therapy. Journal of Medical Genetics, 54(11), 771–780.
   PubMed Web of Science ®Google Scholar
• Ishii, S., Sakuraba, H., & Suzuki, Y. (1992). Point mutations in the upstream region of the α-galactosidase A gene exon 6 in an atypical variant of Fabry disease. Human Genetics, 89(1), 29–32. https://doi.org/10.1007/BF00207037
   PubMed Web of Science ®Google Scholar
• Jamboti, J., & Forrest, C. H. (2017). Fabry disease; early diagnosis improves prognosis but diagnosis is often delayed. Journal of Nephropathology, 6(3), 130–133. https://doi.org/10.15171/jnp.2017.22
   PubMedGoogle Scholar
• Jirásková, A., Bortolussi, G., Dostálová, G., Eremiášová, L., Golaň, L., Danzig, V., Linhart, A., & Vítek, L. (2017). Serum bilirubin levels and promoter variations in HMOX1 and UGT1A1 genes in patients with Fabry disease. Oxidative Medicine and Cellular Longevity, 2017, 9478946. https://doi.org/10.1155/2017/9478946
   PubMed Web of Science ®Google Scholar
• Keighobadi, M., Emami, S., Lagzian, M., Fakhar, M., Rafiei, A., & Valadan, R. (2018). Molecular modeling and structural stability of wild-type and mutant CYP51 from leishmania major: In vitro and in silico analysis of a laboratory strain. Molecules, 23(3), 696. https://doi.org/10.3390/molecules23030696
   PubMed Web of Science ®Google Scholar
• Koide, T., Ishiura, M., Iwai, K., Inoue, M., Kaneda, Y., Okada, Y., & Uchida, T. (1990). A case of Fabry’s disease in a patient with no α‐galactosidase A activity caused by a single amino acid substitution of Pro‐40 by Ser. FEBS Letters, 259(2), 353–356. https://doi.org/10.1016/0014-5793(90)80046-L
   PubMed Web of Science ®Google Scholar
• Kubo, T., Ochi, Y., Baba, Y., Hirota, T., Tanioka, K., Yamasaki, N., Yoshimitsu, M., Higuchi, K., Takenaka, T., Nakajima, K., Togawa, T., Tsukimura, T., Sano, S., Tei, C., Sakuraba, H., & Kitaoka, H. (2017). Prevalence and clinical features of Fabry disease in Japanese male patients with diagnosis of hypertrophic cardiomyopathy. Journal of Cardiology, 69(1), 302–307.
   PubMed Web of Science ®Google Scholar
• Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993). PROCHECK: A program to check the stereochemical quality of protein structures. Journal of Applied Crystallography, 26(2), 283–291. https://doi.org/10.1107/S0021889892009944
   Web of Science ®Google Scholar
• Lenders, M., Weidemann, F., Kurschat, C., Canaan-Kühl, S., Duning, T., Stypmann, J., Schmitz, B., Reiermann, S., Krämer, J., Blaschke, D., Wanner, C., Brand, S.-M., & Brand, E. (2016). Alpha-galactosidase A p. A143T, a non-Fabry disease-causing variant. Orphanet Journal of Rare Diseases, 11(1), 1–9. https://doi.org/10.1186/s13023-016-0441-z
   PubMedGoogle Scholar
• Lidove, O., Jaussaud, R., & Aractingi, S. (2006). Dermatological and soft-tissue manifestations of Fabry disease: Characteristics and response to enzyme replacement therapy. In Fabry disease: Perspectives from 5 years of FOS. Oxford PharmaGenesis.
   Google Scholar
• Lukas, J., Giese, A.-K., Markoff, A., Grittner, U., Kolodny, E., Mascher, H., Lackner, K. J., Meyer, W., Wree, P., Saviouk, V., & Rolfs, A. (2013). Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in Fabry disease. PLoS Genetics, 9(8), e1003632.
   PubMed Web of Science ®Google Scholar
• Lukas, J., Scalia, S., Eichler, S., Pockrandt, A.-M., Dehn, N., Cozma, C., Giese, A.-K., & Rolfs, A. (2016). Functional and clinical consequences of novel α‐galactosidase A mutations in Fabry disease. Human Mutation, 37(1), 43–51.
   PubMed Web of Science ®Google Scholar
• Lobanov, M. I., Bogatyreva, N. S., & Galzitskaia, O. V. (2008). Radius of gyration is indicator of compactness of protein structure. Molekuliarnaia Biologiia, 42(4), 701–706.
   PubMed Web of Science ®Google Scholar
• Muntean, C., Starcea, M., Stoica, C., & Banescu, C. (2022). Clinical characteristics, renal involvement, and therapeutic options in pediatric patients with Fabry disease. Frontiers in Pediatrics, 10, 908657. https://doi.org/10.3389/fped.2022.908657
   PubMed Web of Science ®Google Scholar
• Nance, C. S., Klein, C. J., Banikazemi, M., Dikman, S. H., Phelps, R. G., McArthur, J. C., Rodriguez, M., & Desnick, R. J. (2006). Later-onset Fabry disease: An adult variant presenting with the cramp-fasciculation syndrome. Archives of Neurology, 63(3), 453–457.
   PubMedGoogle Scholar
• Ortiz, A., Germain, D. P., Desnick, R. J., Politei, J., Mauer, M., Burlina, A., Eng, C., Hopkin, R. J., Laney, D., Linhart, A., Waldek, S., Wallace, E., Weidemann, F., & Wilcox, W. R. (2018). Fabry disease revisited: Management and treatment recommendations for adult patients. Molecular Genetics and Metabolism, 123(4), 416–427.
   PubMed Web of Science ®Google Scholar
• Pereira, E. M., do Monte, S. J., do Nascimento, F. F., de Castro, J. A., Sousa, J. L., Filho, H. C., da Silva, R. N., Labilloy, A., Monte Neto, J. T., & da Silva, A. S. (2014). Lysosome-associated protein 1 (LAMP-1) and lysosome-associated protein 2 (LAMP-2) in a larger family carrier of Fabry disease. Gene, 536(1), 118–122. https://doi.org/10.1016/j.gene.2013.11.063
   PubMed Web of Science ®Google Scholar
• Pereira, G. R. C., Da Silva, A. N. R., Do Nascimento, S. S., & De Mesquita, J. F. (2019). In silico analysis and molecular dynamics simulation of human superoxide dismutase 3 (SOD3) genetic variants. Journal of Cellular Biochemistry, 120(3), 3583–3598.
   PubMed Web of Science ®Google Scholar
• Robertson, M. J., Qian, Y., Robinson, M. C., Tirado-Rives, J., & Jorgensen, W. L. (2019). Development and testing of the OPLS-AA/M force field for RNA. Journal of Chemical Theory and Computation, 15(4), 2734–2742.
   PubMed Web of Science ®Google Scholar
• Shabbeer, J., Robinson, M., & Desnick, R. J. (2005). Detection of α‐galactosidase a mutations causing fabry disease by denaturing high performance liquid chromatography. Human Mutation, 25(3), 299–305.
   PubMed Web of Science ®Google Scholar
• Sheng, B., Yim, K. F., Lau, L. K., Lee, H. C. H., Fung, K. S. S., Ma, K. F. J., & Chak, W. L. (2020). Two related Chinese Fabry disease patients with a p. N215S pathological variant who presented with nephropathy. Molecular Genetics and Metabolism Reports, 24, 100596.
   PubMed Web of Science ®Google Scholar
• Singharoy, A., Teo, I., McGreevy, R., Stone, J. E., Zhao, J., & Schulten, K. (2016). Molecular dynamics-based refinement and validation for sub-5 Å cryo-electron microscopy maps. eLife, 5, e16105. https://doi.org/10.7554/eLife.16105
   PubMed Web of Science ®Google Scholar
• Sokkar, P., Harms, M., Stürzel, C., Gilg, A., Kizilsavas, G., Raasholm, M., Preising, N., Wagner, M., Kirchhoff, F., Ständker, L., Weidinger, G., Mayer, B., Münch, J., & Sanchez-Garcia, E. (2021). Computational modeling and experimental validation of the EPI-X4/CXCR4 complex allows rational design of small peptide antagonists. Communications Biology, 4(1), 1–13. https://doi.org/10.1038/s42003-021-02638-5
   PubMed Web of Science ®Google Scholar
• Tubiana, T., Carvaillo, J.-C., Boulard, Y., & Bressanelli, S. (2018). TTClust: A versatile molecular simulation trajectory clustering program with graphical summaries. Journal of Chemical Information and Modeling, 58(11), 2178–2182.
   PubMed Web of Science ®Google Scholar
• Tuttolomondo, A., Simonetta, I., Riolo, R., Todaro, F., Di Chiara, T., Miceli, S., & Pinto, A. (2021). Pathogenesis and molecular mechanisms of Anderson–Fabry disease and possible new molecular addressed therapeutic strategies. International Journal of Molecular Sciences, 22(18), 10088. https://doi.org/10.3390/ijms221810088
   PubMed Web of Science ®Google Scholar
• Varela, P., Mastroianni Kirsztajn, G., Motta, F. L., Martin, R. P., Turaça, L. T., Ferrer, H., Gomes, C. P., Nicolicht, P., Mara Marins, M., Pessoa, J. G., Braga, M. C., D’Almeida, V., Martins, A. M., & Pesquero, J. B. (2020). Correlation between GLA variants and alpha-galactosidase A profile in dried blood spot: An observational study in Brazilian patients. Orphanet Journal of Rare Diseases, 15(1), 30.
   PubMed Web of Science ®Google Scholar
• Zhan, D., Zhou, Z., Guan, S., & Han, W. (2013). The effect of conformational variability of phosphotriesterase upon N-acyl-L-homoserine lactone and paraoxon binding: Insights from molecular dynamics studies. Molecules, 18(12), 15501–15518. https://doi.org/10.3390/molecules181215501
   PubMed Web of Science ®Google Scholar
• Zhao, Y., Zeng, C., & Massiah, M. A. (2015). Molecular dynamics simulation reveals insights into the mechanism of unfolding by the A130T/V mutations within the MID1 zinc-binding Bbox1 domain. PLoS One, 10(4), e0124377. https://doi.org/10.1371/journal.pone.0124377
   PubMed Web of Science ®Google Scholar
• Zhou, W., Liu, Q., Wang, W., Yuan, X. J., Xiao, C. C., & Ye, S. D. (2022). Comprehensive network analysis reveals the targets and potential multitarget drugs of type 2 diabetes mellitus. Oxidative Medicine and Cellular Longevity, 2022, 8255550. https://doi.org/10.1155/2022/8255550
   PubMed Web of Science ®Google Scholar